You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
醫藥股個別造好 翰森、來凱及君實升6%-8% 藥明系受壓
恆指今早低見16,863,創年內新低後喘定,現報17,058,回升64點或0.4%,總成交額723億元。 醫藥股中,以君實生物(01877.HK)表現較好,重上10天及20天線(22.4元、22元),最多升近13%,現報23.6元,升8%。半新股來凱醫藥-B(02105.HK)高見21.9元,現報21.3元,升6%。 康希諾(06185.HK)重越10天及20天線,最高見28元,現報27.25元,升4.2%;康希諾A(688185.SH)升2.6%。 三葉草生物-B(2197.HK)升2.9%報0.72元,重上10天線。諾誠健華(09969.HK)升逾3%。信達生物(01801.HK)重上10天及20天線,最高見45.8元,現報45.15元,升3%。 藍籌翰森(03692.HK)午後高見16.1元,創逾七個月高,現報15.98元,升5.7%;同爲藍籌中生(01177.HK)重上10天及250天線(3.8元及3.83元),午後高見3.87元,現報3.84元,升2.7%。 藍籌石藥(01093.HK)中午公佈,首三季純利按年升0.6%至44.95億人民幣,該股繼半日升不足1%後,下午高見7.16元,現報7.11元,升1.6%。 然而,藍籌藥明生物(02269.HK)三連跌,今天失守百天線(44.5元),最低見42.7元,現報43.35元,跌3%;藥明康德(02359.HK)跌1.7%報91.75元;藥明巨諾-B(02126.HK)低見2.86元,現報3.18元,跌2.5%。掛牌第十天的藥明合聯(02268.HK)報28.65元,跌0.3%。 維亞生物(01873.HK)跌4.1%報1.16元,股價失守10天線。騰盛博藥-B(02137.HK)跌3.4%報2.82元,股價失守10天及20天線。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account